Literature DB >> 20852126

Heparin modifies the immunogenicity of positively charged proteins.

Shalini L Chudasama1, Benjamin Espinasse, Fred Hwang, Rui Qi, Manali Joglekar, Galyna Afonina, Mark R Wiesner, Ian J Welsby, Thomas L Ortel, Gowthami M Arepally.   

Abstract

The immune response in heparin-induced thrombocytopenia is initiated by and directed to large multimolecular complexes of platelet factor 4 (PF4) and heparin (H). We have previously shown that PF4:H multimolecular complexes assemble through electrostatic interactions and, once formed, are highly immunogenic in vivo. Based on these observations, we hypothesized that other positively charged proteins would exhibit similar biologic interactions with H. To test this hypothesis, we selected 2 unrelated positively charged proteins, protamine (PRT) and lysozyme, and studied H-dependent interactions using in vitro and in vivo techniques. Our studies indicate that PRT/H and lysozyme/H, like PF4/H, show H-dependent binding over a range of H concentrations and that formation of complexes occurs at distinct stoichiometric ratios. We show that protein/H complexes are capable of eliciting high-titer antigen-specific antibodies in a murine immunization model and that PRT/H antibodies occur in patients undergoing cardiopulmonary bypass surgery. Finally, our studies indicate that protein/H complexes, but not uncomplexed protein, directly activate dendritic cells in vitro leading to interleukin-12 release. Taken together, these studies indicate that H significantly alters the biophysical and biologic properties of positively charged compounds through formation of multimolecular complexes that lead to dendritic cell activation and trigger immune responses in vivo.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20852126      PMCID: PMC3031390          DOI: 10.1182/blood-2010-06-292938

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  42 in total

1.  Confirmatory procedure and other maneuvers to assess pathogenicity of platelet factor 4 (PF4)-dependent antibodies--distinguishing "signal" from "noise".

Authors:  Theodore E Warkentin
Journal:  Thromb Haemost       Date:  2008-10       Impact factor: 5.249

2.  Platelet factor 4-heparin complexes trigger immune responses independently of the MyD88 pathway.

Authors:  Shayela Suvarna; Rui Qi; John W Hollingsworth; Gowthami M Arepally
Journal:  Br J Haematol       Date:  2008-05-28       Impact factor: 6.998

3.  Safety of protamine sulfate administration in vasectomized men.

Authors:  D Vézina; P Sheridan; R Blain; K D Roberts; G Bleau
Journal:  Contraception       Date:  1990-06       Impact factor: 3.375

4.  Studies of the immune response in heparin-induced thrombocytopenia.

Authors:  Theodore E Warkentin; Jo-Ann I Sheppard; Jane C Moore; Richard J Cook; John G Kelton
Journal:  Blood       Date:  2009-01-14       Impact factor: 22.113

5.  Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Authors:  Jack Hirsh; Kenneth A Bauer; Maria B Donati; Michael Gould; Meyer M Samama; Jeffrey I Weitz
Journal:  Chest       Date:  2008-06       Impact factor: 9.410

Review 6.  Heparan sulphate proteoglycans fine-tune mammalian physiology.

Authors:  Joseph R Bishop; Manuela Schuksz; Jeffrey D Esko
Journal:  Nature       Date:  2007-04-26       Impact factor: 49.962

7.  Anti-heparin/platelet factor 4 antibody optical density values and the confirmatory procedure in the diagnosis of heparin-induced thrombocytopenia.

Authors:  Nicole L Whitlatch; Stephanie L Perry; Thomas L Ortel
Journal:  Thromb Haemost       Date:  2008-10       Impact factor: 5.249

8.  Optimization of a murine immunization model for study of PF4/heparin antibodies.

Authors:  S Suvarna; R Qi; G M Arepally
Journal:  J Thromb Haemost       Date:  2009-02-24       Impact factor: 5.824

9.  Determinants of PF4/heparin immunogenicity.

Authors:  Shayela Suvarna; Benjamin Espinasse; Rui Qi; Rauova Lubica; Mortimer Poncz; Douglas B Cines; Mark R Wiesner; Gowthami M Arepally
Journal:  Blood       Date:  2007-09-11       Impact factor: 22.113

Review 10.  The protamine family of sperm nuclear proteins.

Authors:  Rod Balhorn
Journal:  Genome Biol       Date:  2007       Impact factor: 13.583

View more
  20 in total

Review 1.  Drug-associated thrombocytopenia.

Authors:  Tamam Bakchoul; Irene Marini
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

2.  Disruption of PF4/H multimolecular complex formation with a minimally anticoagulant heparin (ODSH).

Authors:  M V Joglekar; P M Quintana Diez; S Marcus; R Qi; B Espinasse; M R Wiesner; E Pempe; J Liu; D M Monroe; G M Arepally
Journal:  Thromb Haemost       Date:  2012-02-08       Impact factor: 5.249

3.  Pyoderma gangrenosum-like skin changes after subcutaneous administration of low molecular weight heparin.

Authors:  Małgorzata Sobieszczańska; Sławomir Tubek; Ilona Kura
Journal:  Hum Vaccin Immunother       Date:  2014-01-17       Impact factor: 3.452

4.  Serologic characterization of anti-protamine/heparin and anti-PF4/heparin antibodies.

Authors:  Grace M Lee; Manali Joglekar; Maragatha Kuchibhatla; Sanjay Khandelwal; Rui Qi; Lubica Rauova; Gowthami M Arepally
Journal:  Blood Adv       Date:  2017-04-18

5.  Heparin enhances uptake of platelet factor 4/heparin complexes by monocytes and macrophages.

Authors:  M Joglekar; S Khandelwal; D B Cines; M Poncz; L Rauova; G M Arepally
Journal:  J Thromb Haemost       Date:  2015-07-14       Impact factor: 5.824

6.  Protamine-induced immune thrombocytopenia.

Authors:  Atul Singla; Mia J Sullivan; Grace Lee; John Bartholomew; Samir Kapadia; Richard H Aster; Brian R Curtis
Journal:  Transfusion       Date:  2013-02-05       Impact factor: 3.157

7.  High incidence of antibodies to protamine and protamine/heparin complexes in patients undergoing cardiopulmonary bypass.

Authors:  Grace M Lee; Ian J Welsby; Barbara Phillips-Bute; Thomas L Ortel; Gowthami M Arepally
Journal:  Blood       Date:  2013-02-19       Impact factor: 22.113

Review 8.  Immune pathogenesis of heparin-induced thrombocytopenia.

Authors:  Sanjay Khandelwal; Gowthami M Arepally
Journal:  Thromb Haemost       Date:  2016-07-28       Impact factor: 5.249

Review 9.  Advances in the pathophysiology and treatment of heparin-induced thrombocytopenia.

Authors:  Steven E McKenzie; Bruce S Sachais
Journal:  Curr Opin Hematol       Date:  2014-09       Impact factor: 3.284

10.  Regulatory T Cells Control PF4/Heparin Antibody Production in Mice.

Authors:  Yongwei Zheng; Wen Zhu; Dipica Haribhai; Calvin B Williams; Richard H Aster; Renren Wen; Demin Wang
Journal:  J Immunol       Date:  2019-08-30       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.